HEMO ORGANIC LIMITED

CIN - L24231GJ1992PLC018224

Address: Shop 1 to 3, First floor, Piyu Apartment Opp Electricity Sub Station & Mahesh Nagar, Nr. Radhika Chambers & Jay Amarnath Society, Nikol Gam Road, Uttamnagar, Ahmedabad, Gujarat, India – 382 350

Email ID: hemoorganic@gmail.com **Website**: www.hemoorganic.co **Ph. No.** 8238557874

Date: 15th July, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir/Ma'am,

Sub: Submission of Un-audited Financial Results along with Limited Review Report for the Quarter ended on 30th June, 2026

Ref: Scrip Code: 524590 | Symbol: HEMORGANIC | ISIN: INE422G01015

In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Un-audited Financial Results along with Limited Review Report, by the Statutory Auditor of the Company, i.e., M/s. MAAK & Associates, Chartered Accountant, for the quarter ended on 30th June, 2026.

Please take note of the same and oblige.

For, Hemo Organic Limited

VISHWAMBAR KAMESHWAR SINGH
Digitally signed by VISHWAMBAR KAMESHWAR SINGH
Date: 2026.07.15 17:22:09 +05'30'

Vishwambar Kameshwar Singh
Managing Director
DIN: 09822587

MAAK & ASSOCIATES
Chartered Accountants

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS HEMO ORGANIC LIMITED PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE PERIOD ENDED 30th JUNE, 2026

To,

The Board of Directors,
HEMO ORGANIC LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/s HEMO ORGANIC LIMITED for the quarter ended 30th June,2026, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FCA/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, except as specified in Qualified Opinion para, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

MAAK & ASSOCIATES
FRN: 135024W
AHMEDABAD
CHARTERED ACCOUNTANTS

601- 604, Ratnanjali Square, Nr. Gloria Restaurant, Prernatirth Derasar Road, Prahlad Nagar, Ahmedabad - 380015.
: www.maakadvisors.com : 079-4032-3758 : info@maakadvisors.com

Qualified Opinion:

1. We have not been provided with the balance confirmation or any other details for the trade receivable & trade payable in the books of accounts & in the absence of the same we are unable to confirm the balance and nature of the transaction.

Date: 15/07/2026
Place: Ahmedabad
UDIN: 26139533JUQSJQ3583

For, M A A K & Associates
(Chartered Accountants)
F.R.N.:135024W

MAAK & ASSOCIATES
FRN: 135024W
AHMEDABAD
CHARTERED ACCOUNTANTS

CA Kenan Satyawadi
(Partner)
Mem.No.:139533

HEMO ORGANIC LIMITED

CIN: L24231GJ1992PLC018224

Registered Office: Shop 1-3, 1 Floor, Piyu apartment, Opp. Electricity sub station, Jay amarnath society, Nikol, Ahmedabad, Gujarat, India, 382350

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 30th June, 2026

(Rs. In lakh)

	Particulars	Quarter ended on			Year Ended on
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	**Revenue from operations**	-	92.70	0.19	92.90
2	**Other income**	-	-	-	0.20
3	**Total Income (1+2)**	-	**92.70**	**0.19**	**93.10**
4	**Expenses**				
	a. Purchases	-	(29.01)	31.14	2.13
	b. Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	121.79	(31.00)	90.80
	c. Employee benefits expense	1.36	1.10	2.85	6.53
	d. Finance costs	-	-	-	-
	e. Depreciation & amortisation expense	0.01	0.01	0.01	0.06
	f. Other expenses	6.05	28.50	8.64	43.41
	Total Expenses	**7.42**	**122.39**	**11.64**	**142.93**
5	Profit / (Loss) before exceptional items and tax (3-4)	**(7.42)**	**(29.69)**	**(11.45)**	**(49.83)**
6	Exceptional items	-	-	-	-
7	Profit / (Loss) before tax (5+6)	**(7.42)**	**(29.69)**	**(11.45)**	**(49.83)**
8	Tax expense:	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	20.83	(2.88)	27.93
	Tax relating to earlier period	-	0.05	-	0.05
	Total tax expense	-	**20.88**	**(2.88)**	**27.98**
9	Profit (Loss) for the period from continuing operations (7-8)	**(7.42)**	**(50.57)**	**(8.57)**	**(77.81)**
10	Profit/(loss) from discontinuing operations before Tax	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-
13	Profit / (Loss) for the period (9+12)	**(7.42)**	**(50.57)**	**(8.57)**	**(77.81)**
14	**Other Comprehensive Income**				
	Items that will not be reclassified subsequently to profit or loss	-	-	-	-
	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	Items that will be reclassified subsequently to profit or loss	-	-	-	-
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Other Comprehensive Income, net of tax	-	-	-	-
15	**Total Comprehensive Income for the period (13+14)**	**(7.42)**	**(50.57)**	**(8.57)**	**(77.81)**
16	Paid up equity share capital (Face value of Rs. 10 each)	346.59	346.59	346.59	346.59
17	Earnings Per equity share (Face value of Rs. 10 each)				
	1) Basic	(0.21)	(1.46)	(0.25)	(2.24)
	2) Diluted	(0.21)	(1.46)	(0.25)	(2.24)

Place: Ahmedabad
Date : 15/07/2026

HEMO ORGANIC LIMITED

By order of the Board
Hemo Organic Limited

Vishwambhar Singh
Managing Director
DIN: 09822587

Notes:

1 The above standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on 15th July, 2026.

2 The financial results of the company have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the companies Act, 2013 read with relevant rules there under and in terms with regulation 33 of SEBI (Listing Obligation and Disclosures Requirements) regulations 2015 and SEBI circular dated 5th July 2016.

3 The statutory Auditors of the company have carried out a "Limited Review" of the above result as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The IND AS compliant corresponding figures of the previous year have not been subject to review. However the company's management has excercised necessary due diligence to ensure that such financial results provide true and fair view.

4 Earning per share for the quarter and year ended has been calculated as per weighted average formula and diluted Earning per share has been calculated considering proposed issue of equity shares on account of conversion of convertible securities if any.

5 Previous period figures have been reclassified / regrouped wherever considered necessary to confirm to the current period figures.

Date : 15/07/2026
Place: Ahmedabad

By order of the Board
Hemo Organic Limited

HEMO ORGANIC LIMITED

Vishwambhar Singh
Managing Director
DIN: 09822587

HEMO ORGANIC LIMITED
CIN - L24231GJ1992PLC018224
Address: Shop 1 to 3, First floor, Piyu Apartment Opp Electricity Sub Station & Mahesh Nagar, Nr. Radhika Chambers & Jay Amarnath Society, Nikol Gam Road, Uttamnagar, Ahmedabad, Gujarat, India – 382 350
Email ID: hemoorganic@gmail.com **Website**: www.hemoorganic.co **Ph. No.** 8238557874

Date: 15th July, 2026

To,
BSE Limited
Phiroze Jeejeebhoy
Tower,Dalal Street,
Mumbai – 400001.

Dear Sir / Madam,

Sub: Statement on deviation(s) / variation(s) in utilization of proceeds raised through Preferential Issue of convertible warrants, pursuant to Regulation 32 of SEBI (LODR) Regulations, 2015 ("SEBI Listing Regulations) for the quarter ended on June 30, 2026.

Ref: Scrip Code: 524590 | Scrip Symbol: HEMORGANIC | ISIN: INE422G01015

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the statement, in the prescribed format, confirming that there were no deviations or variations in the utilization of proceeds from the Preferential Issue of Convertible Warrants of the Company for the quarter ended June 30, 2026. The said statement was duly reviewed by the Audit Committee at its meeting held today, i.e., July 15, 2026.

You are requested to kindly take the above information on record.

Thanking You,

For, HEMO ORGANIC LIMITED

VISHWAMBAR KAMESHWAR SINGH

Digitally signed by VISHWAMBAR KAMESHWAR SINGH
Date: 2026.07.15 17:22:45 +05'30'

VISHWAMBAR KAMESHWAR SINGH
MANAGING DIRECTOR
DIN: 09822587

<u>STATEMENT OF DEVIATION OR VARIATION FOR PROCEEDS OF PREFERENTIAL ISSUE OF CONVERTIBLE WARRANTS:</u>

Statement on deviation / variation in utilization of funds raised

Name of listed entity	Hemo Organic Limited
Mode of Fund Raising	Preferential Issue of Convertible Warrants
Date of Raising Funds	26th February, 2026 (Date of allotment)
Amount Raised	Rs. 1,06,25,000 (Upfront receipt of 25% of total consideration) (Allotment of 34,00,000 convertible warrants at a price of Rs. 12.50/- (including premium of Rs. 02.50/-)
Report filed for Quater ended	30th June, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the Shareholders	Not Applicable
If Yes, Date of Shareholders Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None
Objects for which funds have been raised in the Right Issue and details of deviation,if any, in the following table:	

(Rs. In lakhs)

Sr. No.	**Object as disclosed in the offer document**	**Original Allocation**	**Proportionate Allocation (25% Received Upfront)**	**Amount utilised till June 30, 2026**	**Unutilised Amount as on June 30, 2026**
1	Working Capital Requirement	318.75	79.69	79.69	-
2	General Corporate Purpose	106.25	26.56	25.71	0.85
		425.00	**106.25**	**105.40**	**0.85**

Notes:

On February 26, 2026, the Company allotted 34,00,000 Convertible Warrants on a preferential basis to "Non-Promoter". Each warrant is issued at a price of 12.50, (including premium of Rs. 02.50/-).

As on the reporting date, the Company has received amount of Rs. 1,06,25,000, (i.e., 25% of the total amount) from allottees as the warrant subscription price. The balance amount of Rs. 3,18,75,000 (i.e., 75% of the issue price) shall be payable by the warrant holders at the time of exercise/ conversion of the warrants.

Each warrant entitles the holder to apply for and be allotted one fully paid-up equity share of the Company having a face value of Rs. 10 each, upon payment of the balance consideration. The warrants may be exercised and converted into equity shares in one or more tranches within a period of 18 months from the date of allotment, in accordance with the applicable provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

The warrants shall remain valid for the aforesaid period, and the warrant holders are entitled to exercise their right of conversion into equity shares within such period in compliance with the applicable SEBI ICDR Regulation

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which funds have been raised; or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or
(c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

For, HEMO ORGANIC LIMITED

VISHWAMBAR KAMESHWAR SINGH

Digitally signed by VISHWAMBAR KAMESHWAR SINGH
Date: 2026.07.15 17:23:05 +05'30'

VISHWAMBAR KAMESHWAR SINGH
MANAGING DIRECTOR
DIN: 09822587

MAAK & ASSOCIATES
Chartered Accountants

UTILIZATION OF FUNDS CERTIFICATE
M/s. Hemo Organic Limited

To,
The Board of Directors,
Hemo Organic Limited.

Respected Sir,

Subject: Certificate pursuant to SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 in relation to the proceeds of the issue from the Preferential Issue of Convertible Warrants for Hemo Organic Limited ("the Company")

We have been requested to certify the utilisation of the proceeds of the issue from the Preferential Issue of Convertible Warrants. For the purpose of certifying the below table, we have reviewed documents, statement, papers, books of accounts, and other relevant information of the Company on the proceeds of Preferential Issue of Convertible Warrants. Based on our review of the same, we hereby certify below:

Objects for which funds have been raised and utilisation thereof:

(Rupees in Lakhs)

Sr. No.	Object as disclosed in the offer document	Original Allocation	Proportionate Allocation (25% Received Upfront)	Amount utilised till June 30, 2026	Unutilised Amount as on June 30, 2026
1	Working Capital Requirement	318.75	79.69	79.69	-
2	General Corporate Purpose	106.25	26.56	25.71	0.85
		425.00	**106.25**	**105.40**	**0.85**

We wish to inform you that there has been no deviation(s) or variation(s) in the use of Preferential Issue of Convertible Warrants proceeds of the Issue, raised from Convertible Warrants by the Company for the quarter ended June 30, 2026.

List of Preferential Issue of Convertible Warrants proceeds received:

(Rupees in Lakhs)

Date	Particulars	Amount
26.02.2026	Proceeds from Preferential Issue of Convertible Warrants	Rs. 106.25 Lakhs (Upfront receipt of 25% of Total Consideration on 34,00,000 warrants)

Notes:

1. On February 26, 2026, the Company allotted 34,00,000 Convertible Equity Share Warrants on a preferential basis to "Non-Promoter" as approved in the Extra-Ordinary General Meeting held on January 07, 2026. Each warrant is issued at a price of 12.50, (including premium of Rs. 02.50/-).

MAAK & ASSOCIATES AHMEDABAD CHARTERED ACCOUNTANTS

2. As on the reporting date, the Company has received amount of Rs. 1,06,25,000, (i.e., 25% of the total amount) from allottees as the warrant subscription price. The balance amount of Rs. 3,18,75,000 (i.e., 75% of the issue price) shall be payable by the warrant holders at the time of exercise/ conversion of the warrants.

3. Each warrant entitles the holder to apply for and be allotted one fully paid-up equity share of the Company having a face value of Rs. 10 each, upon payment of the balance consideration. The warrants may be exercised and converted into equity shares in one or more tranches within a period of 18 months from the date of allotment, in accordance with the applicable provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

4. The warrants shall remain valid for the aforesaid period, and the warrant holders are entitled to exercise their right of conversion into equity shares within such period in compliance with the applicable SEBI ICDR Regulations.

Yours faithfully,

For M A A K & Associates
Chartered Accountants
Firm Reg No: 135024W
Peer Review Certificate No.: 017841

MAAK & ASSOCIATES * FRN: 135024W AHMEDABAD * CHARTERED ACCOUNTANTS

CA Kenan Satywadi
(Partner)
Membership Number: 139533
UDIN: 26139533IRNYZX1079
Place: Ahmedabad
Date: 15 July 2026